오피오이드 사용 장애 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Opioids Use Disorder Market size is expected to reach USD 17.06 Billion in 2034 from USD 6.07 Billion (2025) growing at a CAGR of 12.17% during 2026-2034.

The opioids use disorder market is undergoing significant evolution as healthcare systems prioritize effective treatment strategies and harm reduction measures. Rising prevalence of opioid dependence and overdose incidents has intensified demand for advanced therapeutic interventions, including buprenorphine, methadone, and emerging non-opioid pharmacotherapies. Integrated care models combining medication-assisted treatment (MAT), behavioral therapy, and digital adherence monitoring are becoming essential for long-term recovery outcomes. Regulatory initiatives and public health campaigns are further supporting patient access to innovative therapies.

Technological and clinical advancements are expanding treatment efficacy and accessibility. Digital health platforms provide remote monitoring, predictive risk alerts, and adherence tracking, enabling personalized treatment strategies. Novel drug formulations, including extended-release and sublingual delivery systems, are improving patient compliance while reducing misuse potential. Research into non-addictive analgesics, vaccine-based interventions, and neuromodulation therapies is creating new therapeutic avenues. Healthcare providers are increasingly leveraging telemedicine and mobile health technologies to reach underserved populations and improve intervention success rates.

The future trajectory is defined by integrated public health strategies, policy support, and pharmaceutical innovation. North America remains the largest market due to high prevalence and mature treatment infrastructure, while emerging economies are gradually scaling access to evidence-based therapies. Strategic partnerships between healthcare providers, digital health innovators, and pharmaceutical companies are fostering a comprehensive ecosystem for diagnosis, treatment, and recovery support. As awareness, technology, and therapeutic options expand, the opioids use disorder market is poised to provide more effective, patient-centric solutions that address both medical and societal challenges.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug

• Naltrexone
• Buprenorphine
• Methadone
• Others

By Route of Administration

• Oral Administration
• Injectable Administration
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• Indivior PLC, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Collegium Pharmaceutical BioDelivery Sciences International Inc, Alkermes Inc, Orexo US Inc a part of Orexo AB, Titan Pharmaceuticals Inc, Omeros Corporation, Camurus AB, Hikma Pharmaceuticals PLC
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OPIOIDS USE DISORDER MARKET: BY DRUG 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug
• 4.2. Naltrexone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Buprenorphine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Methadone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OPIOIDS USE DISORDER MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectable Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OPIOIDS USE DISORDER MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL OPIOIDS USE DISORDER MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL OPIOIDS USE DISORDER INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Indivior PLC
  • 9.2.2 Teva Pharmaceutical Industries Ltd
  • 9.2.3 Pfizer Inc
  • 9.2.4 Collegium Pharmaceutical (BioDelivery Sciences International Inc.)
  • 9.2.5 Alkermes Inc
  • 9.2.6 Orexo US Inc. (A Part Of Orexo AB)
  • 9.2.7 Titan Pharmaceuticals Inc
  • 9.2.8 Omeros Corporation
  • 9.2.9 Camurus AB
  • 9.2.10 Hikma Pharmaceuticals PLC